1. Potential and existing impact of vaccines on disease epidemiology;Miller,2003
2. Carlsson RM, Gustafsson L. Ten year report: pertussis surveillance in Sweden. Progress report October 1, 1997–December 31, 2007 with an executive summary. Available from URL: http://www.smittskyddsinstitutet.se/upload/SMI-rapport%20nr%204-2008.pdf [accessed 4 February 2009]. Ten year report, Appendix 1 (Person-time calculations). Available from URL: http://www.smittskyddsinstitutet.se/upload/10-y%20report-app%201.pdf [accessed 4 February 2009]. Ten year report, Appendix 2 (Person-time of follow-up and incidence calculations for GSK vaccine specific cohorts). Available from URL: http://www.smittskyddsinstitutet.se/upload/10-y%20report-app%202%20-%20GSK.pdf [accessed 4 February 2009]. Ten year report, Appendix 2 (Person-time of follow-up and incidence calculations for Sanofi Pasteur vaccine specific cohorts). Available from URL: http://www.smittskyddsinstitutet.se/upload/10-y%20report-app%202-%20SP%20MSD.pdf [accessed 4 February 2009]; 2008.
3. Carlsson RM, Gustafsson L. Ten year report: pertussis in Göteborg study area. Technical report October 1, 1997 until December 31, 2007, including enhanced surveillance January 1, 2003 until December 31, 2007, with an executive summary. Available from URL: http://www.smittskyddsinstitutet.se/upload/SMI-rapport%20nr%205-2008.pdf [accessed 4 February 2009]; 2008.
4. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution;Mooi;Infect Immun,1998
5. Mass vaccination of children with pertussis toxoid—decreased incidence in both vaccinated and nonvaccinated persons;Taranger;Clin Infect Dis,2001